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Inc., Cambridge, MA, USABackground & Aims: Samatasvir is a pan-genotypic inhibitor of
the hepatitis C (HCV) non-structural protein 5A (NS5A). This
study evaluated the antiviral activity, pharmacokinetics and
safety of samatasvir monotherapy in treatment-naïve subjects
infected with HCV genotype 1–4.
Methods: Thirty-four genotype 1 and thirty genotype 2, 3 or 4
subjects were randomized to receive for 3 days placebo or sama-
tasvir 25–100 mg per day. Plasma samples for HCV RNA, pharma-
cokinetics and sequencing were collected up to day 10.
Results: Samatasvir achieved potent antiviral activity across
genotypes: mean maximum reductions from baseline were 3.2–
3.6 (genotype 1a), 3.0–4.3 (genotype 1b), 3.2–3.4 (genotype 3),
and 3.6–3.9 (genotype 4) log10/ml respectively; no viral rebound
was observed during the 3-day treatment period. For genotype 2
HCV, samatasvir was active in subjects with NS5A L31 polymor-
phism at baseline (individual range 2.5–4.1 log10/ml), but showed
minimal activity in those with baseline M31 polymorphism.
Samatasvir exhibited a long plasma half-life of approximately
20 h which supports once daily dosing. Samatasvir was well tol-
erated in all subjects with no safety-related discontinuations or
serious adverse events. The most common adverse events
included constipation, nausea and headache and occurred at sim-Journal of Hepatology 20
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half-life; EC90, 90% effective concentration.ilar frequency in active and placebo subjects. All events were
mild or moderate in intensity. There were no patterns or dose
dependence of adverse events, vital signs, laboratory parameters
or electrocardiograms.
Conclusions: Samatasvir 25–100 mg monotherapy for 3 days
was well tolerated and induced a rapid and profound reduction
in plasma HCV RNA in subjects infected with HCV genotype 1–
4. Samatasvir is being evaluated in combination with other
direct-acting antiviral agents in subjects with HCV infection.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Direct-acting antiviral agents (DAAs) have radically reshaped the
treatment paradigm of chronic hepatitis C virus (HCV) infection.
While pegylated interferon still remains as an essential compo-
nent of the current optimal treatment regimens containing either
telaprevir or boceprevir, major efforts are being devoted towards
the development of interferon-free all oral regimens by combin-
ing multi-class DAAs with or without ribavirin. A number of
newer DAAs with improved safety proﬁle and antiviral activity
are expected to soon receive regulatory approval, bringing better
treatment options to HCV-infected patients [1].
Amongst various classes of DAAs, non-structural protein 5A
(NS5A) replication complex inhibitors have thus far been the
most potent in suppressing viral replication [2,3]. These com-
pounds have been shown to induce multi-log reductions in
plasma HCV RNA within h of a single low dose [4,5]. While
NS5A inhibitors are most active against HCV genotype 1b, many
showed much less replicon activity against other genotypes, par-
ticularly genotype 2 and genotype 3 [2,3]. Considering the high
prevalence of multiple HCV genotypes across many geographic
regions, it is highly desirable for a DAA to possess pan-genotypic
antiviral activity [6]. In that context, several newer NS5A inhibi-14 vol. 60 j 920–927
Fig. 1. Chemical structure of samatasvir.
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tors with in vitro pan-genotypic antiviral activity are being devel-
oped (samatasvir, ACH-3102, GS5816, PPI668) [2,3]. To our
knowledge, among these candidates, samatasvir, as a single
agent, was the ﬁrst to demonstrate pan-genotypic activity in
HCV-infected patients [5].
Samatasvir (IDX719), a novel NS5A inhibitor of HCV replica-
tion, exhibits potent and pan-genotypic anti-HCV activity with
in vitro 50% effective concentration (EC50) values ranging from
2 to 24 pM against HCV of genotypes 1a, 1b, 2a, 3a, 4a, and 5a.
There is only a 12-fold shift in EC50 values from the most sensi-
tive genotype 4a to the least sensitive genotype 2a. With a 50%
cytotoxicity concentration >50 lM, samatasvir has a high selec-
tivity index of at least 2,000,000 [7,8]. Fig. 1 illustrates the chem-
ical structure of samatasvir.
Samatasvir showed limited or no inhibition of human CYP
enzymes or human transporters, and underwent very limited
metabolism in vitro. In replicon studies, samatasvir demonstrated
additive antiviral activity with other HCV therapeutic agents and
no negative pharmacodynamic interaction with commonly used
antiviral agents against hepatitis B (HBV) and human immunode-
ﬁciency virus (HIV). Together, these favorable characteristics
make samatasvir an ideal component of all-oral DAA regimens [8].
Samatasvir was evaluated in a two-part clinical study. Part one
included single-dose escalation and repeat dose administration in
healthy subjects and an exploratory single-dose administration in
subjects infected with HCV genotype 1, 2 or 3. Results from part
one, reported elsewhere, showed that single and repeat doses of
samatasvir up to 100 mg in healthy volunteers and single doses up
to 100mg in HCV-infected subjects were well-tolerated and
achieved pharmacologically relevant drug exposure. Samatasvir
exhibited dose-proportional plasma exposure and long plasma
half-life, supportingoncedaily (QD)dosing [5]. Singledoses of sama-
tasvir demonstrated substantial pan-genotypic antiviral activity of
up to 3.7 log10 IU/ml in patients with genotype 1, 2 or 3 HCV [5].
Part two of the study, reported here, evaluated the safety,
pharmacokinetics (PK) and antiviral activity of samatasvir as a
single agent following multiple doses up to 100 mg daily for
3 days in subjects infected with HCV genotype 1, 2, 3 or 4.Materials and methods
Study design
This was a multicenter, randomized, double-blind, placebo-controlled, parallel-
panel, multiple-dose study of samatasvir as a single agent dosed for 3 days in
treatment-naïve patients with chronic HCV genotype 1, 2, 3 or 4. Thirty-four
patients with genotype 1 HCV were randomized to receive either samatasvir
(n = 28) or placebo (n = 6): 25 mg and 50 mg QD cohorts each had 8 active and
2 placebo subjects; 50 mg twice daily (BID) and 100 mg QD cohorts each had 6
active and 1 placebo subjects. Thirty subjects with HCV genotype 2, 3 or 4 were
randomized to receive samatasvir 50 mg BID (n = 12), 100 mg QD (n = 12) or pla-
cebo (n = 6) in an active-to-placebo ratio of 4:1 (ClinicalTrials.gov Identiﬁer:
NCT01508156). Treatment was assigned via a computer-generated randomiza-
tion code and kept blinded to subjects and clinical investigators. Subjects were
admitted to one of the 8 clinical sites in the United States between January 3,
2012 and July 9, 2012 and were required to stay in the clinical facility from
day 1 to study discharge on day 10 or upon early termination. Samatasvir oral
suspension or matching placebo was administered under fasting conditions.
Cohorts were dosed in parallel without dose escalation.
Written informed consent was obtained from all patients. This study was
approved by the institutional review boards of the trial centers and conducted
in accordance with Good Clinical Practice procedures and the principles of the
Declaration of Helsinki, with authorization from the United States Food and Drug
Administration.Journal of Hepatology 201The sample size of this study was calculated primarily based on safety end-
points. With a sample size of 4, 6 or 8 subjects per cohort to receive active sama-
tasvir, the estimated probabilities of observing a particular adverse event (AE)
with an expected rate of 20% were 0.59, 0.74, and 0.83, respectively. It was
assumed that for this short-term study safety risk would be independent of
HCV genotypes or dosing regimen (BID and QD) for the same daily dose. When
pooled together across genotypes, the sample size for subjects receiving active
samatasvir 50 mg BID or 100 mg QD was 36 leading to an estimated chance of
98% to observe a particular AE with an expected incidence rate of at least 20%.
Subjects
Major inclusion criteria included: male or female subjects 18–65 years old inclu-
sive, with a body mass index (BMI) of 18–35 kg/m2; documented clinical history
compatible with chronic HCV, including positive anti-HCV antibody, presence of
HCV RNA in the plasma for at least six months or liver biopsy within 24 months
with histology consistent with chronic HCV infection; HCV genotype 1, 2, 3 or 4;
plasma HCV RNA P5 log10 IU/ml; all patients agreed to use double-barrier birth
control (such as a condom plus spermicide) from screening through at least
90 days following the last dose of the study drug.
Major exclusion criteria included: pregnancy or breastfeeding; co-infection
with HBV or HIV; history or evidence of decompensated liver disease; prior clin-
ical or histological evidence of cirrhosis; alanine aminotransferase or aspartate
aminotransferase level >3.0  upper limit of normal; history of hepatocellular
carcinoma (HCC) or ﬁndings suggestive of possible HCC; one or more additional
known primary or secondary causes of liver disease, other than HCV; previous
antiviral treatment for HCV; current abuse of alcohol or illicit drugs; or other clin-
ically signiﬁcant diseases that, in the opinion of the investigator, would jeopar-
dize the safety of the patient or impact the validity of the study results.
Safety assessments
At speciﬁc time points throughout the study, blood and urine samples were col-
lected for clinical laboratory analysis including hematology, blood chemistry and
urinalysis. Vital signs, 12-lead electrocardiogram (ECG) and physical examina-
tions were performed at predeﬁned time intervals. Safety assessments were
based on observed/reported AEs and serious adverse events (SAEs) as well as
results from clinical laboratory tests, vital sign measurements, physical examina-
tion and ECGs.
Pharmacokinetics
For QD dosing, serial intensive blood samples for PK analysis were collected over
24 h on day 1 and over 120 h after the last dose on day 3 at the following time
points: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24 h postdose on day 1 and
day 3, and 36, 48, 72, 96, and 120 h post the day-3 dose. For BID dosing, blood
samples were obtained predose in the morning (AM) and evening (PM) and at
0.5, 1, 2, 3, 4, 6, and 8 h postdose on day 1 and day 3. In addition, blood samples
were obtained at 12, 24, 36, 60, 84, and 108 h post the day-3 PM dose. PK param-
eters derived from non-compartmental analysis included maximum drug concen-
tration (Cmax), time to Cmax (Tmax), predose trough concentration (Cs) at 24 h post
QD dose or 12 h post BID dose, area under the plasma concentration-time curve
over 24 h for the total daily dose (AUC24h), and observed half-life (t1/2) calculated
following the last dose. Plasma concentrations of samatasvir were measured
using a validated liquid chromatography/tandem mass spectrometry methodol-
ogy. All samples were analyzed within the established stability of the analyte.4 vol. 60 j 920–927 921
Research Article
Brieﬂy, internal standard 13C5-15N-samatasvir was added to calibration standards
(0.1 to 100 mg/ml), quality control samples (0.3–80 ng/ml) and unknown sam-
ples. The mixture was subject to liquid-liquid extraction with a recovery of
87.1% and 96.3% for samatasvir and the internal standard respectively. Chroma-
tography was performed on a ZORBAX 300-SCX column (50 mm  3 mm; particle
size, 5 lm, Agilent Technologies, Santa Clara, CA). Elution was carried out isocrat-
ically at a constant ﬂow rate of 1 ml/min with a mobile phase of 80:20 (v/v) ace-
tonitrile : ammonium formate (25 mM, pH 2.5). Under these conditions, the
retention time was approximately 0.96 min for samatasvir and internal standard.
Mass spectrometry data were acquired using an AB Sciex API 5500 triple quadru-
pole mass analyzer (Framingham, MA) at mass transition of 443.3?659.2 m/z
and 446.3?659.2 m/z for samatasvir and 13C5-15N-samatasvir respectively. The
mass analyzer was operated under positive ion mode using turbo ion spray ion-
ization. This assay has a lower limit of quantitation of 0.1 ng/ml. The intra- and
inter-day precisions (coefﬁcient of variation) and accuracies (percent deviation)
were from 2.0 to 5.1% and 9.1 to 2.7%, respectively.
Antiviral activity
Serial blood samples for measuring plasma HCV RNA were obtained during
screening, on day 1, during dosing from day 1 to day 3 (day 1 predose and post-
dose at 4, 8, 12, 16, 24, 48, and 72 h) and during follow-up from day 4 to day 9 or
10 (post day 1 dose at 96, 120, 144, 168, 192, and 216 or 240 h). Plasma HCV RNA
was determined by a validated real-time polymerase chain reaction assay
(COBAS AmpliPrep/COBAS Taqman HCV Test, Roche, Pleasanton, CA) with a
lower limit of quantitation of 25 IU/ml.
NS5A sequence analysis
Plasma samples were collected predose on day 1 as well as on day 4 (1 day after
the last dose) and day 10 (1 week post the last dose). Samples with viral load
>1000 IU/ml were subjected to population sequencing of the NS5A region of
the virus at DDL Diagnostic Laboratory (Rijswijk, The Netherlands).Table 1. Demographics and baseline characteristics.
25 mg 
n = 8
50
n 
Mean age, yr (range) 45.1 (4.2) 48
Male, n (%) 5 (62.5) 7 
Race, n (%)
White 7 (87.5) 7 
African American 1 (12.5) 1 
Other 0 0
Mean BMI, kg/m2 (range) 26.1 (1.7) 26
Mean baseline HCV RNA, log10 IU/ml 6.6 (0.18) 5.
HCV genotype
1a 5 6
1b 3 2
2 0 0
2b 0 0
3a 0 0
4 0 0
IL28B genotype, n
CC 3 3
CT 4 3
TT 1 2
QD, once daily; BID, twice daily; BMI, body mass index.
922 Journal of Hepatology 201Statistical analysis
Antiviral activity was measured as the changes on log10 scale from baseline in
plasma HCV RNA. The primary endpoint of antiviral activity was the log10 change
from baseline to day 4. Secondary endpoints included individual maximum viral
load reduction and corresponding time. Antiviral activity data were summarized
by dose for each genotype and/or sub-genotype. Additional exploratory analyses
by stepwise and logistic regression were performed to identify PK and baseline
predictors of viral response. The baseline characteristics included gender, weight,
BMI, race, pretreatment HCV RNA, HCV genotype and IL28B genotype.
PK parameters were summarized by dose regardless of HCV genotypes. AEs
were tabulated by system organ class, preferred term and dose. Other safety data
including vital signs, ECG and clinical laboratory results were summarized by
dose for each scheduled measurement.
All statistical analyses were performed using SAS (Version 9.2, SAS Institute
Inc., Cary, NC).Results
Baseline characteristics
In total, 64 treatment-naïve subjects with genotype 1, 2, 3 or 4
chronic HCV infection were enrolled and completed the 3-day
treatment. Of the 64 subjects, 34 had genotype 1 HCV (mostly
1a; 1a/1b:29/5), and 10 each had genotype 2, genotype 3 or geno-
type 4. One placebo subject typed as being infected with geno-
type 2b HCV at baseline was subsequently determined by direct
sequencing to be infected with genotype 2b/1a chimeric virus.
Most (approximately two-thirds) of the subjects with genotype
1 (23/34) or genotype 2–4 (21/30) HCV had IL28B genotype CTQD BID Placebo
 mg 
= 8
100 mg 
n = 18
50 mg 
n = 18 n = 12
.8 (3.2) 41.9 (2.1) 46.3 (2.4) 44.7 (3.2)
(87.5) 14 (77.8) 12 (66.7) 8 (66.7)
(87.5) 15 (83.3) 13 (72.2) 11 (91.7)
(12.5) 3 (16.7) 4 (22.2) 1 (8.3)
0 1 (5.6) 0
.9 (1.1) 26.2 (0.8) 25.6 (0.7) 28.3 (0.9)
9 (0.12) 6.5 (0.13) 6.3 (0.11) 6.3 (0.18)
6 6 6
0 0 0
1 1 1
3 3 1
4 4 2
4 4 2
6 4 4
9 11 8
3 3 0
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Fig. 2. Plasma HCV RNA, genotypes 1, 3 and 4. Mean (+ standard error) reduction from baseline in plasma HCV RNA in subjects with genotype 1, 3 or 4 HCV.
JOURNAL OF HEPATOLOGYor TT. Subjects were predominantly male and Caucasian. Approx-
imately one-third of the subjects were female. Baseline and
demographic characteristics were comparable across dose groups
(Table 1).
Antiviral activity
Mean changes over time of plasma HCV RNA from baseline are
shown in Fig. 2 for subjects with genotype 1, 3 or 4 HCV. Fig 3
depicts the individual and mean changes over time of plasma
HCV RNA from baseline for subjects with genotype 2 HCV. The
mean change in log10 HCV RNA from baseline to 24 h and 72 h,
the mean maximum change from baseline and the corresponding
time were summarized in Table 2. Samatasvir dosed QD or BID
for 3 days produced substantial pan-genotypic antiviral activity.
The greatest antiviral activity was achieved in subjects having
genotype 1b HCV with mean maximum decrease in HCV RNA
of 3.0–4.3 log10, followed by 3.6–3.9 log10 in genotype 4, 3.2–
3.6 log10 in genotype 1a and 3.2–3.4 log10 in genotype 3 HCV
(see below for antiviral response in subjects with genotype 2
HCV). Maximum decrease in HCV RNA typically occurred uponJournal of Hepatology 201completion of dosing. Antiviral activity was not observed in sub-
jects receiving placebo. After completion of samatasvir dosing,
plasma HCV RNA slowly returned towards baseline but did not
attain pre-treatment level within the follow-up period of up to
10 days.
Antiviral response to samatasvir in subjects with genotype 2
HCV was determined by a single polymorphism at the NS5A
amino acid position 31. Among the 8 subjects with genotype 2
HCV who received samatasvir, high antiviral activity with maxi-
mum decrease in HCV RNA of 4.0 and 4.1 log10 was achieved in
2 subjects (Fig. 3, 002–006 and 004–019) who had L31 at baseline
with no detectable M31 on day 4. In 2 subjects who had L31 at
baseline but emergence of M31on day 4, robust antiviral activity
was retained with maximum decrease in HCV RNA of 2.5 and 3.2
log10 (Fig. 3, 001–147 and 001–163). In 1 subject who had an L/
M31 mixture at baseline but M31 on day 4, a much reduced anti-
viral activity (a decrease of 0.8 log10) was obtained (Fig. 3, 007–
004). Virtually no antiviral activity (0.3–0.5 log10 reduction)
was observed in the 3 subjects with pre-existing M31 who
received samatasvir (Fig. 3, 001–188, 002–017, and 002–016).
In contrast, despite all genotype 4 -infected subjects carrying4 vol. 60 j 920–927 923
Table 2. Summary antiviral activity of samatasvir in subjects with HCV genotype 1, 2, 3 or 4.
Endpoint GT Placebo QD BID
25 mg 50 mg 100 mg 50 mg
Mean (min, max;  n) change 
from baseline to 24 h in HCV 
RNA, log10
1a 0.1 (-0.1, 0.3; 6) 3.1 (2.4, 3.5; 6) 3.2 (2.9, 3.3; 6) 3.2 (2.6, 3.8; 6) 2.7 (1.2, 3.7; 6)
1b - 2.6 (2.0, 3.7; 3) 3.4 (3.3, 3.5; 2) - -
2 0.3 (0.1, 0.2; 2) - - 1.8 (0.1, 3.6; 4) 1.7 (0.2, 3.4; 4)
3 -0.1 (-0.5, 0.3; 2) - - 2.9 (2.4, 3.6; 4) 2.7 (2.0, 3.7; 4)
4 0.0 (0.0-0.13; 2) - - 3.2 (2.4, 3.7; 4) 2.9 (1.6, 3.7; 4)
Mean (min, max) change from 
baseline to 72 h in HCV RNA, 
log10
1a 0.1 (-0.1, 0.2) 3.1 (2.5, 3.6) 3.6 (3.3, 3.9) 3.1 (2.2, 4.2) 2.9 (2.3, 3.6)
1b - 2.8 (1.6, 4.1) 4.1 (4.0, 4.2) - -
2 0.2 (0.1, 0.2) - - 1.8 (0.1, 3.6) 1.7 (0.2, 3.4)
3 0.1 (0, 0.3) - - 3.2 (2.8, 3.9) 3.0 (2.1, 4.3)
4 0.1 (-0.3, 0.5) - - 3.8 (2.2, 4.6) 3.6 (2.6, 4.5)
Mean (min, max) maximum 
change from baseline in 
HCV RNA, log10
1a 0.4 (0.2-0.6) 3.3 (2.9, 3.7) 3.6 (3.3, 3.9) 3.5 (2.6, 4.3) 3.2 (2.7, 3.8)
1b - 3.0 (2.0, 4.3) 4.3 (4.1, 4.5) - -
2 0.4 (0.3-0.5) - - 2.0 (0.3, 4.1) 2.0 (0.5, 4.0)
3 0.5 (0.4-0.5) - - 3.4 (3.1, 3.9) 3.2 (2.5, 4.3)
4 0.6 (0.4-0.7) - - 3.6 (2.4, 4.6) 3.9 (3.5, 4.5)
Median (min, max) time to 
maximum change, day
1a - 2.0 (0.7, 3.0) 2.3 (2.0, 5.0) 1.5 (0.7, 4.0) 3.0 (1.0, 4.0)
1b - 2.0 (1.0, 5.0) 4.0 (4.0, 4.0) - -
2 - - - 0.8 (0.3, 3.0) 1.7 (0.3, 4.0)
3 - - - 2.0 (1.0, 3.0) 2.5 (1.5, 3.5)
4 - - - 2.5 (1.0, 3.0) 2.9 (2.5, 6.0)
GT, genotype; QD, once-daily; BID, twice-daily; -, not available.
Research Articlean NS5A M31 at baseline, all responded well to samatasvir treat-
ment (Fig. 2). Additional details on sequence analyses of other
studied HCV genotypes will be reported elsewhere.
Pharmacokinetics
Fig. 4 depicts the mean day-3 plasma concentration vs. time pro-
ﬁles over the ﬁrst 24 h after dosing, corresponding to the
intended QD dosing interval. Table 3 summarizes PK parameters
of samatasvir.
Following oral administration in HCV-infected subjects at
daily doses of 25, 50, and 100 mg, samatasvir exhibited dose-
related plasma exposures. Peak exposures were reached with a
median time of 3–4 h postdose. With a half-life of approximately
20 h, plasma samatasvir increased over time with a mean accu-
mulation ratio of approximately 50% based on trough exposures
for QD dosing. For the same total daily dose, samatasvir 50 mg
BID achieved higher trough exposures than did the 100 mg QD
dose although no marked differences in antiviral activity were
noted between the two regimens. Both 100 mg QD and 50 mg
BID reached trough concentrations that were at least 7 fold above
the protein-binding adjusted 90% effective concentration (EC90)
of samatasvir against the least susceptible HCV genotype (geno-
type 2a, EC90 = 2.3 ng/ml), while plasma concentrations of sama-
tasvir remained above the EC90 over the entire dosing interval
after multiple dosing for all doses/regimens (Fig. 4).
Predictors of antiviral response
Among various baseline characteristics and doses examined
using regression analysis, only genotype and dose were signiﬁ-
cant predictors of viral response (p <0.0001). Genotype 1b was
the most susceptible followed by 1a, 3, and 4, which responded924 Journal of Hepatology 201comparably to samatasvir; genotype 2 was the least susceptible
due to high prevalence of the pre-existing M31 or M/L31 poly-
morphisms which virtually did not respond to samatasvir.
Safety and tolerability
Samatasvir was well-tolerated in all subjects. There were no
treatment-emergent deaths, SAEs or safety-related discontinua-
tions. AEs were reported at a similar frequency in samatasvir-
treated subjects (20 of 48 or 41.7%) and placebo (6 of 12 or
50.0%). As summarized in Table 4, the most frequent AEs reported
were constipation, headache, and nausea. All AEs were mild or
moderate in intensity and did not appear to be dose related.
There were no apparent dose-related or other patterns of
newly occurring or worsening graded hematology, chemistry, or
urinalysis abnormalities. There were no clinically signiﬁcant
treatment-emergent changes in vital sign measurements, physi-
cal examination ﬁndings or ECG parameters.Discussion
NS5A replication complex inhibitors are among the most potent
DAAs: as a class, these agents at low doses are capable of produc-
ing multi-log reductions in plasma HCV RNA within hours of dos-
ing [4,5]. Other common features of NS5A inhibitors including
good safety/tolerability, lack of cross-resistance with other clas-
ses of DAAs and once daily dosing make these agents ideal candi-
dates for all oral combination therapy for HCV [3]. While clinical
stage NS5A inhibitors all demonstrated antiviral activity against
genotype 1a/1b HCV as a single agent in their respective proof-
of-concept studies, clinical data on activity against other HCV
genotypes are scarce [3]. To our knowledge, as monotherapy,4 vol. 60 j 920–927
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Fig. 3. Plasma HCV RNA, genotypes 2. Individual and mean (+ standard error) reduction from baseline in plasma HCV RNA in subjects with genotype 2 HCV.
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JOURNAL OF HEPATOLOGYsamatasvir was the ﬁrst to demonstrate potent pan-genotypic
activity in HCV-infected subjects [5]. In an initial exploratory
phase of the current study, single doses of 25–100 mg samatasvir
afforded a maximum reduction in plasma HCV RNA of up to 3.7
log10 in subjects with genotype 2 or 3 HCV, similar to genotype
1 [5].
The samatasvir doses for the 3-day proof-of-concept phase
were selected based on the single-dose antiviral activity in
HCV-infected subjects as well as in vitro antiviral activity against
various HCV genotypes [7,8]. While a single low dose of 1 mg
samatasvir was able to produce over 3 log10 reduction in plasma
HCV RNA, dose-response analyses using data from the single-
dose phase suggested that doses of 25 mg and above might
achieve more consistent antiviral effect [5]. Therefore, doses of
25–100 mg/day were selected for the 3-day dosing in subjects
with genotype 1 HCV. Samatasvir exhibits potent and slightly dif-
ferential in vitro antiviral activity against the more sensitive
genotype 1a/1b and genotype 4a replicons (EC50: 2.0–6.2 pM)
and the less sensitive genotype 2 (EC50 = 24 pM) and genotype
3 (EC50 = 17 pM) [7,8]. These in vitro data in conjunction with
the single-dose anti-HCV activity observed in patients with geno-
type 2 or 3 in part 1 of the study favored the 100 mg/day dose in
subjects with these genotypes in the 3-day dosing phase.cokinetic proﬁles over 24 h of samatasvir.
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Table 3. Summary pharmacokinetics of samatasvir in subjects with HCV genotype 1, 2, 3 or 4.
Dose (mg)/ 
regimen
N Day Cmax 
(ng/ml)
Tmax 
(h)
AUC 24 h 
(ng*h/ml)
Cτ 
(ng/ml)
t1/2 
(h)
25 QD 8 1 13.5 ± 5.19 4.0 (3.0-4.0) 142 ± 44.5 2.93 ± 0.98 (1.76-4.91) -
3 20.0 ± 6.74 4.0 (3.0-6.0) 235 ± 79.9 5.20 ± 2.02 (3.00-8.15) 20.8 ± 4.06
50 QD 8 1 36.0 ± 20.0 4.0 (3.0-4.0) 384 ± 204 6.81 ± 3.68 (2.78-13.0) -
3 32.4 ± 8.12 4.0 (2.0-4.0) 387 ± 115 8.20 ± 2.75 (5.17-13.2) 23.0 ± 3.81
100 QD 18 1 50.9 ± 24.0 4.0 (2.0-6.0) 520 ± 234 10.7 ± 4.61 (6.01-23.4) -
3 65.3 ± 33.0 3.0 (2.0-4.0) 728 ± 344 15.6 ± 6.44 (6.03-25.9) 20.4 ± 3.32
50 BID 18 1, AM 33.9 ± 17.6 3.0 (3.0-4.0) - 11.7 ± 6.95 (2.98-25.5) -
1, PM 21.4 ± 7.40 4.0 (0.0-12) 438 ± 180 15.5 ± 6.90 (5.32-29.6) -
3, AM 49.4 ± 18.3 3.0 (2.0-4.0) - 20.8 ± 9.31 (9.86-42.0) -
3, PM 27.2 ± 10.5 3.0 (1.0-8.0) 681 ± 259 20.8 ± 6.65 (6.49-43.1) 19.7 ± 4.68
Values are reported as mean ± standard deviation, except for Tmax where medians (min-max) are reported. For Cs, (min-max) is also shown.
For BID, AUC24h is the sum of the AM and PM AUC12h (not shown).
AM, morning; PM, evening; -, not applicable; Cs, C24h for QD and C12h for BID.
Table 4. Number (%) of subjects with adverse events regardless of attributability (>5% in any group).
Adverse events QD BID Any dose/regimen Placebo
25 mg 
(n = 8)
50 mg 
(n = 8)
100 mg 
(n = 18)
50 mg 
(n = 18)
 
(n = 48)
 
(n = 12)
Constipation 0 1 (12.5) 3 (16.7) 1 (5.6) 5 (10.4) 2 (16.7)
Headache 0 1 (12.5) 4 (22.2) 1 (5.6) 6 (12.5) 1 (8.3)
Nausea 0 0 2 (11.1) 2 (11.1) 4 (8.3) 1 (8.3)
Catheter site pruritus 1 (12.5) 0 2 (11.1) 0 2 (4.2) 0
Dyspepsia 0 0 0 2 (11.1) 2 (4.2) 1 (8.3)
Decreased appetite 1 (12.5) 0 0 0 1 (2.1) 1 (8.3)
Insomnia 0 1 (12.5) 0 0 1 (2.1) 1 (8.3)
QD, once-daily; BID, twice-daily.
Research ArticleResults from the current 3-day proof-of-concept part of the
study conﬁrmed the pan-genotypic antiviral activity observed
during the exploratory single-dose phase, but showed more pro-
found and persistent virologic response due to continuous sup-
pressive pressure resulting from multiple doses. Subjects with
genotype 1 HCV achieved mean maximum reduction of plasma
HCV RNA of 3.0–4.3 log10, which is numerically in the upper
2.3–4.0 log10 range of virologic response obtained with other
clinical stage NS5A inhibitors as a single agent dosed for 1 to
14 days (median 3 days) [9–17]. At the tested doses administered
for 3 days in subjects with genotype 3 or 4 HCV, virologic
responses were comparable with those observed in genotype 1
subjects with a mean maximum reduction of 3.2–3.9 log10. A sim-
ilar degree of viral suppression was also achieved in subjects with
genotype 2 HCV who had no pre-existing M31 or L/M31 polymor-
phism. Pre-existing M31 polymorphism in genotype 2 subjects
predicts lack of virologic response, and emerging M31 is associ-
ated with reduced antiviral activity to samatasvir monotherapy.
While all current clinical-stage NS5A inhibitors are able to
induce substantial early viral response, this class of HCV DAA
is, however, prone to rapidly select viral variants as a single agent
[3]. Indeed, viruses in the current study underwent treatment-
emergent selection of NS5A variants associated with in vitro
resistance (primarily at positions 93, 28, 30, and 31, details to
be presented elsewhere) although no subject experienced an
on-treatment rebound deﬁned as a 0.5 log10 increase above nadir
with samatasvir as a single agent dosed for 3 days. During a 14-926 Journal of Hepatology 201day monotherapy with daclatasvir, viral rebounds occurred early
(generally before 7 days) and were associated with emergence of
resistant variants [4]. The lack of viral breakthrough while on
samatasvir in the current study contrasts with the observed rapid
selection of resistance-associated variants. These conﬂicting
observations might be a consequence of the short duration of
treatment, i.e., the treatment-selected variants may not have
had sufﬁcient time to rebound from their suppressed levels in
the presence of the drug. The low barrier to resistance with
NS5A inhibitors as monotherapy appears to have little clinical
relevance when these drugs are used in combination with other
classes of DAAs including nucleotide, non-nucleotide NS5B and
protease inhibitors. In fact, the majority of the best sustained
virologic response data (>90%) obtained to date are from experi-
mental all-oral combination regimens involving NS5A inhibitors
[18–21].
Samatasvir exhibited a consistent and long plasma half-life of
20 h across doses/regimens. Its long half-life is in the range of 12–
16 h and 13–50 h reported respectively for daclatasvir and ledi-
pasvir, the most advanced NS5A inhibitors in clinical develop-
ment [9,10]. Long half-life results in sustained plasma
exposures and supports QD dosing of samatasvir. Despite being
able to achieve higher trough concentrations, for the same total
daily dose of 100 mg, samatasvir dosed BID did not produce more
virologic response than QD dosing, presumably due to the fact
that both regimens resulted in troughs largely surpassing the
protein-binding adjusted 90% effective concentration (EC90) of4 vol. 60 j 920–927
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the drug against the tested HCV genotypes. Albeit limited number
of subjects for each (sub)-genotype per cohort and rather compa-
rable viral declines across most genotypes, a multivariate analy-
sis was able to identify HCV genotype and dose as the only
predictors of antiviral response. In this 3-day trial with samatas-
vir as a single agent, subjects with genotype 1b HCV had the best
response followed by genotype 1a, 3 or 4 with similar responses.
Subjects with genotype-2 HCV having emerging M31, pre-exist-
ing M31 or M/L31 polymorphisms had reduced to no response
to samatasvir. Therefore, the relative clinical potencies of sama-
tasvir observed in the present study against various HCV geno-
types were in good agreement with in vitro data [7,8].
Traditional predictors of viral response including baseline viral
load and IL28B polymorphism were not signiﬁcant predictors.
During this short-term proof-of-concept study, samatasvir
was well tolerated with no dose-related safety ﬁndings. While
its safety and tolerability will need to be further deﬁned in
longer-term/larger trials, clinical data to date have shown satis-
factory safety proﬁles for NS5A inhibitors as a class [3].
In conclusion, at the tested doses of 25–100 mg/day for
3 days, samatasvir was safe and demonstrated substantial pan-
genotypic antiviral activity in treatment-naïve patients infected
with genotype 1, 2, 3 or 4 HCV. The pharmacokinetic and antiviral
proﬁles of samatasvir make it a desirable component in all-oral
DAA combination regimens. A phase II study of once-daily sama-
tasvir in combination with simeprevir in treatment-naïve
patients with genotype 1b or 4 HCV is ongoing.Financial support
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